Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy Chuan LiuGuangwei ZhangTi Wen Review Article 05 November 2021 Pages: 1549 - 1567
Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice Xiaoxiao JinXiaotao LiuChuanlai Shen Original Article 01 November 2021 Pages: 1569 - 1582
TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer Luciana GneoNagy RizkallaGary Middleton Original Article Open access 02 November 2021 Pages: 1583 - 1596
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy Luya CaiXuedan DuWenfeng Li Original Article Open access 03 November 2021 Pages: 1597 - 1609
Redirecting host preexisting influenza A virus immunity for cancer immunotherapy Bharat K. R. ChagantySongbo QiuZhen Fan Original Article 03 November 2021 Pages: 1611 - 1623
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study Xiangling ChuHuiping QiangChunxia Su Original Article 07 November 2021 Pages: 1625 - 1631
Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis Jun-shuai XueHui LiuTao Li Original Article 08 November 2021 Pages: 1633 - 1644
Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer Yang ShenXiao-long LiLiu-sheng Peng Original Article 12 November 2021 Pages: 1645 - 1654
Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells Trefa M. AbdullahJacqueline WhatmorePaul Eggleton Original Article Open access 20 November 2021 Pages: 1655 - 1669
Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells Grace LeeSheela KarunanithiDavid Wald Original Article 23 November 2021 Pages: 1671 - 1680
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy Qiaoyun TanLiyuan DaiYuankai Shi Original Article 24 November 2021 Pages: 1681 - 1691
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study Wenxian WangXiaodong GuZhengbo Song Original Article 24 November 2021 Pages: 1693 - 1703
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens Gerulf HänelCaroline AngererMarion Subklewe Original Article Open access 25 November 2021 Pages: 1705 - 1718
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study Geoffroy BilgerNicolas GirardMarie Ange Massiani Original Article 25 November 2021 Pages: 1719 - 1731
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway Tao LuMing LiLijie Tan Original Article 27 November 2021 Pages: 1733 - 1746
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab Mathilde BureauThierry ChatellierElvire Pons-Tostivint Original Article 28 November 2021 Pages: 1747 - 1756
Identification of prognostic genes in the pancreatic adenocarcinoma immune microenvironment by integrated bioinformatics analysis Haolan WangLiqing LuYongheng Chen Original Article 02 December 2021 Pages: 1757 - 1769
Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies Audrey PageEmilie LaurentFloriane Fusil Research Report Open access 08 November 2021 Pages: 1771 - 1775
Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy Matteo BelloneMarco BregniMario P. Colombo Letter to the Editors 09 November 2021 Pages: 1777 - 1786
Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020 Matteo BelloneArianna BreviMario Paolo Colombo Letter to the Editors 16 January 2022 Pages: 1787 - 1794
